LONDON (Alliance News) - Scancell Holdings PLC on Monday said the Japanese Patent Office has granted a patent providing protection for its Moditope immunotherapy platform.
The cancer treatment developer said the Japanese patent covers using any citrullinated tumour-associated T cell epitope to treat patients with cancer. It has an expiry date of August 2033.
Scancell said this grant in Japan follows patents in the US, Europe, South Africa and Australia, and acceptance for granting in China.
"We are pleased to announce the grant of this patent for Moditope in Japan, further extending our IP protection around this platform," said Chief Executive Cliff Holloway.
"We look forward to continuing to advance Modi-1, the first product from this platform, towards clinical development," added Holloway..
Scancell shares were trading 3.1% higher on Monday at 5.26 pence each.
Scancell Holdings (SCLP)